

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2005 (06.05.2005)

PCT

(10) International Publication Number  
**WO 2005/039492 A3**

(51) International Patent Classification<sup>7</sup>: **A01N 63/00**

(21) International Application Number:  
PCT/US2004/034625

(22) International Filing Date: 21 October 2004 (21.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/512,923 22 October 2003 (22.10.2003) US

(71) Applicant (for all designated States except US): **THE JOHN HOPKINS UNIVERSITY** [US/US]; 3400 N. Charles Street, 5th Floor, Baltimore, MD 21218 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DANG, Long** [US/US]; 2225 Rogene Drive, #101, Baltimore, MD 21209 (US). **BETTEGOWDA, Chetan** [US/US]; 2201 Rogene Dr. Apt. #T2, Baltimore, MD 21209 (US). **KINZLER, Kenneth, W.** [US/US]; 1403 Halkirk Way, Bel Air, MD 21015 (US). **VOGELSTEIN, Bert** [US/US]; 3700 Breton Way, Baltimore, MD 21208 (US).

(74) Agent: **KAGAN, Sarah, A.**; Banner & Witcoff, Ltd., 11th floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
30 June 2005

**(15) Information about Correction:**

**Previous Correction:**

see PCT Gazette No. 22/2005 of 2 June 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **IMPROVED COMBINATION BACTERIOLYTIC THERAPY FOR THE TREATMENT OF TUMORS**

(57) **Abstract:** Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by spore-laden bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.

WO 2005/039492 A3